Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -448.41% is 20% below its 1-year average of -374.30%, near the low end of its 1-year range (-495.30%–-41.30%).
5.66% below its 12-month average of -424.38%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -338.44%.
EBITDA MARGIN
-448.41%
EBITDA MARGIN AVG TTM
-424.38%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-5.66%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Kura Oncology, Inc.
Market Cap
$934.79M
EBITDA Margin
-448.41%
TTM Avg
-424.38%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$929.83M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$923.53M
EBITDA Margin
-64.07%
TTM Avg
-61.50%
3Y Avg
-81.15%
5Y Avg
-81.15%
Market Cap
$921.06M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$952.91M
EBITDA Margin
-19083.66%
TTM Avg
-19083.66%
3Y Avg
-19083.66%
5Y Avg
-24221442.25%
Market Cap
$953.81M
EBITDA Margin
-1113.67%
TTM Avg
-2254.05%
3Y Avg
-2254.05%
5Y Avg
-2254.05%
Market Cap
$914.73M
EBITDA Margin
20.95%
TTM Avg
21.20%
3Y Avg
20.44%
5Y Avg
19.67%
Market Cap
$973.93M
EBITDA Margin
17.12%
TTM Avg
8.95%
3Y Avg
16.20%
5Y Avg
17.02%
Market Cap
$978.09M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kura Oncology, Inc. (KURA) | $934.79M | -448.41% | -424.38% | N/A | N/A |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $929.83M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $923.53M | -64.07% | -61.50% | -81.15% | -81.15% |
| MoonLake Immunotherapeutics (MLTX)vs › | $921.06M | N/A | N/A | N/A | N/A |
| Savara Inc. (SVRA)vs › | $952.91M | -19083.66% | -19083.66% | -19083.66% | -24221442.25% |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | -1113.67% | -2254.05% | -2254.05% | -2254.05% |
| HealthStream, Inc. (HSTM)vs › | $914.73M | 20.95% | 21.20% | 20.44% | 19.67% |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 17.12% | 8.95% | 16.20% | 17.02% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | N/A | N/A | N/A | N/A |
Gross Margin
94.7%
EBITDA Margin
-448.4%
Operating Margin
-449.9%
Net Margin
-384.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -338.44% |
| 2026-03-31 | -429.56% |
| 2025-12-31 | -495.30% |
| 2025-09-30 | -384.74% |
| 2025-06-30 | -473.85% |
| 2025-03-31 | -456.90% |
| 2024-12-31 | -41.30% |
